# NCT05608252 (NCT05608252)

> VS-6766+Abema+Fulv in Met HR+/HER- BC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05608252
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Adrienne G. Waks
- Conditions: Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions: VS-6766; Abemaciclib; Fulvestrant
- Enrollment: 63
- Primary outcome: Phase 1 Maximum tolerated dose (MTD)
- Primary outcome: Phase 1 Recommended Phase II Dose (RP2D)
- Primary outcome: Phase 2 Clinical benefit rate (CBR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05608252